Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 9/20 | 0.59 |
| ▸ | QDPR | P09417 | 3/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1882237 | 0.76 | ALDH1A1 (0.52) | ALDH1A1 | |
| SCHEMBL3899585 | 0.75 | SIGMAR1 (0.92) | HTR2CQDPRSIGMAR1ALDH1A1NAMPT | |
| SCHEMBL8380936 | 0.75 | QDPR (1.00) | HTR2CQDPRSIGMAR1NAMPT | |
| SCHEMBL531984 | 0.75 | SIGMAR1 (1.00) | HTR2CQDPRSIGMAR1HTR2AHTR6 | |
| SCHEMBL4671168 | 0.75 | HTR2C (0.66) | HTR2CQDPRSIGMAR1ALDH1A1HTR2A | |
| SCHEMBL19998281 | 0.75 | HTR2C (0.66) | HTR2CQDPRSIGMAR1ALDH1A1NAMPT | |
| SCHEMBL5603685 | 0.75 | HTR2C (0.66) | HTR2CQDPRSIGMAR1NAMPTHTR6 | |
| SCHEMBL1199051 | 0.75 | HTR2C (1.00) | HTR2CQDPRSIGMAR1NAMPTHTR2A | |
| SCHEMBL532892 | 0.75 | HTR2C (0.66) | HTR2CQDPRSIGMAR1HTR2AHTR6 | |
| SCHEMBL8310253 | 0.75 | HTR2C (0.66) | HTR2CQDPRSIGMAR1ALDH1A1NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8012979-B2 | Compounds and their uses 707 | ASTRAZENECA AB (SE) | 2011-09-06 | — | — | US | disclosed |
| WO-2009050248-A1 | SUBSTITUTED PIPERIDINO-DIHYDROTHIENOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-23 | — | — | WO | disclosed |
| US-20090023746-A1 | COMPOUNDS AND THEIR USES 707 | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023746-A1 | COMPOUNDS AND THEIR USES 707 | CYP3A7, UGT1A7, UGT2B7 | HTR2C 822/4885QDPR 68/4885SIGMAR1 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.